Request Demo
Last update 22 Sep 2025
Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine)
Last update 22 Sep 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD70 modulators(CD70 antigen modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine)NCT07184450
Clinical Study of BCMA/CD70 Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) in the Treatment of Refractory Pediatric Rheumatic Diseases
NCT06934447
Study of BCMA/CD70 Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Childhood-oneset Systemic Lupus Erythematosus
NCT06553898
Study of Therapeutic Efficacy of Anti-B Cell Maturation Antigen（BCMA）/Cluster of Differentiation 70(CD70 )CAR-T Cells in Patients With Multi-drug Resistant SRNS
100 Clinical Results associated with Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data
100 Translational Medicine associated with Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data
100 Patents (Medical) associated with Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data
100 Deals associated with Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatomyositis | Phase 1 | China | 01 Sep 2025 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 1 | China | 01 Sep 2025 | |
| Primary Sjögren's syndrome | Phase 1 | China | 01 Sep 2025 | |
| Scleroderma, Systemic | Phase 1 | China | 01 Sep 2025 | |
| Carney Complex | Phase 1 | China | 25 Apr 2025 | |
| Carney Complex | Phase 1 | China | 25 Apr 2025 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 25 Apr 2025 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 25 Apr 2025 | |
| Nephrotic Syndrome | Phase 1 | China | 13 Aug 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free